Development of treatment for HER2 or EGFR exon 20 insertion mutation-driven NSCLC

被引：0
|
作者：
Ninomiya, Kiichiro [1 ]
机构：
[1] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol Oncol & Resp Med, Okayama, Japan
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.05.478
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SY20-3
引用
收藏
页码：S444 / S444
页数：1
相关论文
共 50 条
  • [31] Clinicopathological Characteristics for NSCLC Harboring EGFR Exon 20 Insertion
    Morikawa, K.
    Kakinuma, K.
    Inoue, T.
    Mineshita, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S496 - S496
  • [32] First case report of sunvozertinib for the treatment of HER2 exon 20 insertion in lung adenocarcinoma
    Luan, Tao
    Lin, Xinqing
    Xie, Xiaohong
    Yang, Gang
    Wang, Shuaiying
    Hao, Jianqing
    Zhou, Chengzhi
    ANTI-CANCER DRUGS, 2024, 35 (08) : 757 - 760
  • [33] Updated Efficacy, Safety and Dosing Management of Poziotinib in Previously Treated EGFR and HER2 Exon 20 NSCLC Patients
    Cornelissen, R.
    Garassino, M. C.
    Le, X.
    Clarke, J.
    Tchekmedyian, N.
    Goldman, J.
    Lebel, F.
    Bhat, G.
    Socinski, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S173 - S174
  • [34] Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease
    Metro, Giulio
    De Giglio, Andrea
    Ricciuti, Biagio
    Siringo, Marco
    Marinelli, Daniele
    Gelibter, Alain
    Pecci, Federica
    Berardi, Rossana
    Cantini, Luca
    Di Federico, Alessandro
    Andrini, Elisa
    Mosca, Mirta
    Lamberti, Giuseppe
    Brambilla, Marta
    Mountzios, Giannis
    DRUGS IN CONTEXT, 2022, 11
  • [35] Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions
    Madison, Russell W.
    Gupta, Sumati V.
    Elamin, Yasir Y.
    Lin, Douglas I.
    Pal, Sumanta K.
    Necchi, Andrea
    Miller, Vincent A.
    Ross, Jeffrey S.
    Chung, Jon H.
    Alexander, Brian M.
    Schrock, Alexa B.
    Heymach, John V.
    Reddy, Prasanth
    Ali, Siraj M.
    BJU INTERNATIONAL, 2020, 125 (05) : 739 - 746
  • [36] Tumor Tissue and Plasma EGFR Exon 20 Insertion Mutation Status in NSCLC Patients Treated with Sunvozertinib
    Wang, M.
    Fan, Y.
    Sun, M.
    Wang, Y.
    Zhao, Y.
    Jin, B.
    Hu, Y.
    Han, Z.
    Song, X.
    Liu, A.
    Tang, K.
    Ding, C.
    Liang, L.
    Wu, L.
    Gao, J.
    Wang, J.
    Cheng, Y.
    Zhou, J.
    He, Y.
    Dong, X.
    Yao, Y.
    Yu, Y.
    Wang, H.
    Sun, S.
    Huang, J.
    Fang, J.
    Li, W.
    Wang, L.
    Ren, X.
    Zhou, C.
    Hu, Y.
    Zhao, D.
    Yang, R.
    Xu, F.
    Huang, Y.
    Pan, Y.
    Cui, J.
    Xu, Y.
    Zhu, X.
    Shi, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S150 - S150
  • [37] Prevalence And Outcomes of EGFR Exon 20 Insertion Mutation In NSCLC: Princess Margaret Cancer Center Experience
    Mittal, A.
    Hueniken, K.
    Cheng, S.
    Zhan, L. J.
    Brown, C.
    Mai, V.
    Lee, J.
    Adewole, O. O.
    Herman, J.
    Sabouhanian, A.
    Storm, E.
    Chowdhury, M. T.
    Moore, A.
    Walia, P.
    Hoxha, T.
    Parker, J.
    Patel, D.
    Balantaram, K.
    Khan, K.
    Garcia, M.
    Schimd, S.
    Sacher, A. G.
    Bradbury, P. A.
    Shepherd, F. A.
    Leighl, N. B.
    Liu, G.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S245 - S245
  • [38] Author Correction: EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
    Alex Friedlaender
    Vivek Subbiah
    Alessandro Russo
    Giuseppe Luigi Banna
    Umberto Malapelle
    Christian Rolfo
    Alfredo Addeo
    Nature Reviews Clinical Oncology, 2022, 19 : 70 - 70
  • [39] EGFR exon 20 insertion mutation in Japanese lung cancer
    Sasaki, Hidefumi
    Endo, Katsuhiko
    Takada, Minoru
    Kawahara, Masaaki
    Kitahara, Naoto
    Tanaka, Hisaichi
    Okumura, Meinoshin
    Matsumura, Akihide
    Luchi, Keiji
    Kawaguchi, Tomoya
    Kawano, Osamu
    Yukiue, Haruhiro
    Yokoyama, Tomoki
    Yano, Motoki
    Fujii, Yoshitaka
    LUNG CANCER, 2007, 58 (03) : 324 - 328
  • [40] Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations
    Lee, Yusoo
    Kim, Tae Min
    Kim, Dong-Wan
    Kim, Soyeon
    Kim, Miso
    Keam, Bhumsuk
    Ku, Ja-Lok
    Heo, Dae Seog
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (09) : 1556 - 1566
12345